Literature DB >> 6166691

Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

G H Scullard, R B Pollard, J L Smith, S L Sacks, P B Gregory, W S Robinson, T C Merigan.   

Abstract

Twenty patients with chronic active hepatitis and 12 patients with chronic persistent hepatitis associated with hepatitis B virus (HBV) infection were treated with human leukocyte interferon or adenine arabinoside alone or in combination. With interferon alone, four of 16 patients showed a permanent disappearance of HBV-associated DNA polymerase (DNAP) activity from serum. Of six patients treated with adenine arabinoside alone, only one patient became permanently DNAP-negative. With a regimen of multiple cycles of combined interferon and adenine arabinoside, seven of 16 male patients became permanently DNAP-negative. Of 69 patients who met the criteria for admission to the program, spontaneous decreases in DNAP activity without treatment were observed in only 9% during a mean observation period of 10 months. In general, patients with chronic active hepatitis, those who are female, and those with a history of recent steroid therapy responded to the antiviral agents significantly better than did the other patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166691     DOI: 10.1093/infdis/143.6.772

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.

Authors:  Y K Yoo; J B Gavaler; K Chen; T L Whiteside; D H van Thiel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 3.  Randomised placebo controlled trials in HIV infection: to be or not to be?

Authors:  K Gelmon; I V Weller
Journal:  Genitourin Med       Date:  1989-06

4.  Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.

Authors:  I V Weller; A S Lok; A Mindel; P Karayiannis; S Galpin; J Monjardino; S Sherlock; H C Thomas
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

5.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

6.  Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase.

Authors:  D F Smee; S S Knight; A E Duke; W S Robinson; T R Matthews; P L Marion
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

7.  Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.

Authors:  D Shouval; J R Wands; V R Zurawski; K J Isselbacher; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

8.  Psychosocial impact of chronic infection with hepatitis B virus on British patients.

Authors:  A S Lok; D J van Leeuwen; H C Thomas; S Sherlock
Journal:  Genitourin Med       Date:  1985-08

9.  Permanent HBsAg clearance in chronic hepatitis B viral infection following acute delta superinfection.

Authors:  K P Chin; S Govindarajan; A G Redeker
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

10.  Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Authors:  M Eisenberg; S Rosno; G Garcia; M W Konrad; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.